Bangladesh Pharma Leaders Call For Higher Drug-Production Standards
This article was originally published in PharmAsia News
Bangladesh's pharmaceutical industry, led by Beximco, Incepta and Square, is growing at the rate of 15% a year, but needs more testing laboratories to maintain standards, industry leaders say.
You may also be interested in...
Chugai is pursuing further Japanese litigation over generic rivals to its Edirol brand, this time concerning the eldecalcitol ingredient produced by Nissan Chemical.
The European Commission has unexpectedly concluded that CBD should not be considered as a drug opening up the path to a regulated EU market for the cannabinoid as a novel food.
As Apotex names its new US president and CEO, Akorn puts together a fresh board of directors following bankruptcy proceedings. Stada has made new appointments in Germany, while Siegfried makes significant changes in its leadership roles.